A practical reference on Chromatographic purity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-23 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
== SoBe Beverages == Upon his departure from the NFL, Bello took a position as VP Marketing with Brooklyn, New York-based Ferolito, Vultaggio and Sons, makers of AriZona iced tea. At AriZona he joined a former Pepsi colleague Mike Schott, then COO of AriZona Beverages. After four months he left AriZona to create his own beverage company in partnership with Tom Schwalm that became the South Beach Beverage Company, named after the trendy South Beach area of Miami. The new company, based in Norwalk, Connecticut, marketed so-called "New Age" beverages—exotic juice blends and ready-to-drink iced teas—but faced formidable competition from its predecessors, including Snapple, Mystic, Nantucket Nectars and AriZona. South Beach needed a point of differentiation in the marketplace, so Bello added trace elements of various herbs and nutrients—such as ginseng, ginkgo biloba, guarana, carnitine, Echinacea, yohimbe, taurine and praline—and promoted their benefits beyond hydration. He launched a "3G" line of drinks, which included supposed energy boosters like ginseng, ginkgo biloba and guarana. He also expanded the brand's iced tea portfolio to include more exotic offerings such as Black Tea, Oolong Tea (with bee pollen), Green Tea (with Echinacea) and Red Tea (with selenium).
==== Kahn criteria ==== The Kahn criteria require serological criteria in addition to Raynaud's phenomenon and two out of the three symptoms listed below (swelling of the fingers, myositis, and synovitis) to qualify for a diagnosis of MCTD. It has a sensitivity of 63% and a specificity of 86%. Serological criteria:
Chevreul was born in the town of Angers, France, where his father was a physician. Chevreul's birth certificate, kept in the registry book of Angers, bears the signature of his father, grandfather, and a great-uncle, all of whom were surgeons. At around the age of seventeen, Chevreul went to Paris and entered L. N. Vauquelin's chemical laboratory, afterwards becoming his assistant at the Muséum national d'histoire naturelle (National Museum of Natural History) in the Jardin des Plantes. In 1813, Chevreul was appointed professor of chemistry at the Lycée Charlemagne, and subsequently undertook the directorship of the Gobelins tapestry works, where he carried out his research on colour contrasts. (In 1839, he published the results of his research under the title De la loi du contraste simultané des couleurs; It was translated into English and published in 1854 under the title The Principles of Harmony and Contrast of Colors. A new translation titled On the Law of Simultaneous Contrast of Colors, with commentary, additional chapters, and colour graphics by Dan Margulis, appeared in 2020.) In 1826, Chevreul became a member of the Academy of Sciences, and in the same year was elected a foreign member of the Royal Society of London, whose Copley Medal he was awarded in 1857. In 1829, he was elected a foreign member of the Royal Swedish Academy of Sciences and a Foreign Honorary Member of the American Academy of Arts and Sciences in 1868.
Sources: en.wikipedia.org
== GREAT Trust == The Gaza Reconstitution, Economic Acceleration and Transformation (GREAT) Trust is a proposed post-war reconstruction initiative for the Gaza Strip, outlined in a 38-page prospectus circulated within the Trump administration. The plan, which was devised by some of the same individuals behind the Gaza Humanitarian Foundation (GHF), is for a US-led multilateral trusteeship to govern Gaza after the disarmament of Hamas, transitioning from initial US-Israel bilateral control to broader international involvement, with Israel retaining overarching security rights. Its core goals are stated as redesigning Gaza's layout, economy, and governance and integrating it into the India–Middle East–Europe Economic Corridor (IMEC). Key components include 10 large projects under public-private partnerships (PPPs), such as rebuilding infrastructure (e.g., clearing unexploded ordnance and debris), highways and trams (e.g., the "MBS Ring" named after Saudi Crown Prince Mohammed bin Salman), an "Elon Musk Smart Manufacturing Zone" along the Gaza-Israel border, US-regulated data centers, a small port and airport, and luxury resorts with artificial islands. The plan would entail the "voluntary" temporary relocation of Gaza's 2 million+ population during reconstruction, with incentives like $5,000 per person cash bonuses, rent and food subsidies, and the assumption that 25% (about 500,000 people) would leave permanently. The plan has been criticized as a form of ethnic cleansing and forced displacement through a profit-driven exploitation.
=== Vaccination === By 2006, China has successfully immunised 11.1 million children living in the country's poorest provinces against hepatitis B according to the Chinese health ministry, and the Global Alliance for Vaccines and Immunization (GAVI). However, China still has a long way to go before immunisation levels reach a percentage able to limit the spread of hepatitis B. China's health minister, Gao Qiang told a Beijing press conference that the project, while effective, has covered only one third of all children born in China since the project began in 2002. This does not mean the rest of China's children went unvaccinated. However, even within the project's target area, over one million newborns went unvaccinated each year because of access issues; health-care costs, lack of birth attendants, and the remoteness of their birthplaces, such as herder's huts, mountain villages, and remote farms. Until 2005, when a law banning the practice was passed, parents were charged fees for the administration of the vaccine. Even though the GAVI alliance (whose partners include UNICEF and the WHO), and Chinese government were providing the vaccine and one-use needles free of charge, health-care workers charged fees that parents were unwilling or unable to pay. Based on a 1992 epidemiological survey, the disease burden of those who are chronically infected with hepatitis B in China is estimated to be at 120 million, one third of the overall burden (360 million) as estimated by the WHO. China's national target is to reach greater than 85% vaccination.
== Structure and mechanism == Despite having only four choices for each monomer unit (nucleotides), compared to 20 amino acid side chains found in proteins, ribozymes have diverse structures and mechanisms. In many cases they are able to mimic the mechanism used by their protein counterparts. For example, in self cleaving ribozyme RNAs, an in-line SN2 reaction is carried out using the 2' hydroxyl group as a nucleophile attacking the bridging phosphate and causing 5' oxygen of the N+1 base to act as a leaving group. In comparison, RNase A, a protein that catalyzes the same reaction, uses a coordinating histidine and lysine to act as a base to attack the phosphate backbone. Like many protein enzymes, metal binding is also critical to the function of many ribozymes. Often these interactions use both the phosphate backbone and the base of the nucleotide, causing drastic conformational changes. There are two mechanism classes for the cleavage of a phosphodiester backbone in the presence of metal. In the first mechanism, the internal 2'- OH group attacks the phosphorus center in a SN2 mechanism. Metal ions promote this reaction by first coordinating the phosphate oxygen and later stabling the oxyanion. The second mechanism also follows a SN2 displacement, but the nucleophile comes from water or exogenous hydroxyl groups rather than RNA itself. The smallest ribozyme is UUU, which can promote the cleavage between G and A of the GAAA tetranucleotide via the first mechanism in the presence of Mn2+.
== Impact of the altered protein binding == Only the unbound fraction of the drug undergoes metabolism in the liver and other tissues. As the drug dissociates from the protein, more and more drug undergoes metabolism. Changes in the levels of free drug change the volume of distribution because free drug may distribute into the tissues leading to a decrease in plasma concentration profile. For the drugs which rapidly undergo metabolism, clearance is dependent on the hepatic blood flow. For drugs which slowly undergo metabolism, changes in the unbound fraction of the drug directly change the clearance of the drug. The most commonly used methods for measuring drug concentration levels in the plasma measure bound as well as unbound fractions of the drug. The fraction unbound can be altered by a number of variables, such as the concentration of drug in the body, the amount and quality of plasma protein, and other drugs that bind to plasma proteins. Higher drug concentrations would lead to a higher fraction unbound, because the plasma protein would be saturated with drug and any excess drug would be unbound. If the amount of plasma protein is decreased (such as in catabolism, malnutrition, liver disease, renal disease), there would also be a higher fraction unbound. Additionally, the quality of the plasma protein may affect how many drug-binding sites there are on the protein.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.